Wave Immune is developing a new generation of oral PD‑L1 inhibitors that reactivate antitumor immunity with antibody‑like efficacy, while offering simpler administration, improved tolerability, and uniquely strong brain penetration. Lead candidate has shown robust preclinical activity, positioning the company to address major unmet needs such as treatment‑resistant tumors and brain metastases. Backed by strong IP, a de‑risked development plan, and an experienced founding team with deep big-pharma experience, Wave Immune is emerging as a disruptive, high‑value player in a PD‑1/PD‑L1 market exceeding $200 billion in 2032. The company is now seeking €3.5 million in seed/Series A financing to advance into IND‑enabling development.
